01 — PRESERVE
Maintain existing technology and IP
Continue evaluating, protecting, developing, licensing, partnering, and commercializing the Company's biotechnology intellectual property and related development assets.
GCAN is evolving into a broader growth platform focused on strategic acquisitions, operational development, technology, intellectual property, and disciplined long-term value creation.
The Company continues to preserve and evaluate the biotechnology intellectual property, therapeutic development assets, and scientific relationships established through its historical operations while pursuing complementary businesses and new strategic opportunities.
GCAN is not abandoning its historical business. The Company is broadening its scope so that existing intellectual property can be preserved, utilized, partnered, licensed, or commercialized as part of a more expansive corporate strategy.
GCAN is an entrepreneurial public company focused on identifying, acquiring, developing, and operating businesses and technologies with meaningful long-term growth potential.
The Company's strategy is intentionally flexible. Rather than limiting its future to a single product, asset, or industry, GCAN intends to evaluate opportunities on their individual merits, including their management quality, market position, scalability, technology, operating potential, and capacity to create durable enterprise value.
GCAN seeks to combine experienced leadership, strategic capital, public-company access, disciplined execution, and active operational involvement to help promising businesses and technologies achieve their potential.
GCAN's next phase is designed to protect the value already created while giving the Company the flexibility to pursue a significantly broader range of growth opportunities.
Continue evaluating, protecting, developing, licensing, partnering, and commercializing the Company's biotechnology intellectual property and related development assets.
Identify businesses, technologies, and strategic assets where management experience, capital, and operational discipline can accelerate growth and improve value.
Develop a stronger, broader company capable of generating value through multiple operating, technology, licensing, partnership, and acquisition channels.
GCAN's historical biotechnology operations generated intellectual property, therapeutic development assets, scientific relationships, and research initiatives that remain part of the Company's business foundation.
GCAN intends to evaluate those assets through a range of potential pathways, including development, licensing, strategic collaboration, joint ventures, commercialization, and other arrangements that may maximize their value.
The Company's broader strategy is designed to complement—not replace—this portfolio.
GCAN intends to approach growth with the discipline of an owner, the flexibility of an entrepreneur, and the accountability of a public company.
We evaluate opportunities based on strategic fit, economics, leadership, scalability, risk, and long-term value—not simply transaction volume.
We seek to contribute management experience, strategic relationships, structure, accountability, and focused execution.
Potential transactions may include acquisitions, mergers, joint ventures, licensing, strategic investments, partnerships, and other structures.
We intend to deploy capital thoughtfully across acquisitions, internal growth, technology development, and strategic opportunities.
Mr. Sanchez Talavera brings extensive experience in acquisitions, regulated financial services, telecommunications infrastructure, restructuring, and special situations.
As a Managing Partner of Trafalgar Asset Management, he has participated in the development, acquisition, operation, and restructuring of companies across multiple sectors and jurisdictions. His experience provides GCANRx with an entrepreneurial, transaction-oriented, and operationally focused perspective as the Company enters its next phase.
Investor RelationsLearn more about the Company's acquisition strategy, technology portfolio, and investor resources.
© 2026 The Greater Cannabis Company, Inc. All Rights Reserved.